Improving olaparib exposure to optimize adverse effects management.

Marylise SterléAlicja PuszkielChloé BurlotEva PereiraAudrey BellesoeurSixtine De PercinGuillaume BeinseJean-David FumetLaure FavierJulie NiogretBenoit BlanchetBernard RoyerLeïla Bengrine-LefevreAntonin Schmitt

Published in: Therapeutic advances in medical oncology (2024)

Based on real-world data, we were able to properly describe the time course of haemoglobinaemia and plasma creatininaemia during olaparib treatment.

Keyphrases

combination therapy
replacement therapy
smoking cessation